ntx-301
Nucleic acidexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Mar 31, 2020 (NCT04167917)
Timeline
2020s
- Jan 1, 2020
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- DNA (cytosine-5)-methyltransferase 1ANTISENSE INHIBITOR
DNMT1 antisense inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04851834 | Phase 1/Phase 2 (Phase 2) | Jul 12, 2021 | Pinotbio, Inc., Xennials Therapeutics Australia Pty Ltd |
| NCT04167917 | Phase 1 | Mar 31, 2020 | University of Alabama, Birmingham |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Pinotbio, Inc. | For profit | 1 | 0 | 1 | 2021 |
| University of Alabama, Birmingham | Academic/Hospital | 1 | 1 | 1 | 2020 |
| Xennials Therapeutics Australia Pty Ltd | For profit | 1 | 1 | 1 | 2021 |
3 organizations
Page 1 / 1